Tina Marriott - 15 Nov 2022 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role: President and COO
Signature: /s/ Jonathan Golightly, attorney-in-fact
Issuer symbol: RXRX
Transactions as of: 15 Nov 2022
Net transactions value: -$175,674
Form type: 4
Filing time: 17 Nov 2022, 17:46:38 UTC
Previous filing: 28 Oct 2022
Next filing: 30 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXRX	Class A Common Stock	Tax liability	$17,233	-1,453	-0.71%	$11.86	203,654	15 Nov 2022	Direct	F1
transaction	RXRX	Class A Common Stock	Options Exercise	$16,960	+16,000	+7.9%	$1.06^*	219,654	17 Nov 2022	Direct	F2
transaction	RXRX	Class A Common Stock	Sale	$175,402	-16,000	-7.3%	$10.96	203,654	17 Nov 2022	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RXRX	Stock Option (Right to Buy)	Options Exercise	$0	-16,000	-2.7%	$0.000000	570,000	17 Nov 2022	Class A Common Stock	16,000	$1.06	Direct	F2, F4
holding	RXRX	Stock Option (Right to Buy)						159,226	15 Nov 2022	Class A Common Stock	0	$11.40	Direct	F5
holding	RXRX	Stock Option (Right to Buy)						4,784	15 Nov 2022	Class A Common Stock	0	$11.40	Direct
holding	RXRX	Stock Option (Right to Buy)						150,000	15 Nov 2022	Class A Common Stock	0	$2.47	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F2	Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person.
F3	The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.78 to $11.32 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F4	Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date.
F5	The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F6	One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date.